CareDx (STU:1K9) Beneish M-Score: -3.57 (As of Jul. 01, 2026)


STU:1K9 CareDx Inc STU:1K9
74 GF Score
Price €25.60
GF Value €18.45
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CareDx Beneish M-Score?

CareDx STU:1K9 -3.13% 74 Beneish M-Score is -3.57 as of Jul. 01, 2026. GuruFocus rates STU:1K9 with a GF Score™ of 74/100 and a GF Value™ of €18.45 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, CareDx ranks better than 88.66% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CareDx's Beneish M-Score or its related term are showing as below:

STU:1K9' s Beneish M-Score Range Over the Past 10 Years
Min: -3.57   Med: -2.76   Max: -0.7
Current: -3.57

During the past 13 years, the highest Beneish M-Score of CareDx was -0.70. The lowest was -3.57. And the median was -2.76.


CareDx Beneish M-Score Historical Data

* Premium members only.

The historical data trend for CareDx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CareDx Beneish M-Score Chart

CareDx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.89 -2.88 -3.48 -3.10 -3.26

CareDx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -3.05 -3.46 -3.26 -3.57

STU:1K9 vs PSNL, OPK, NEO: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, CareDx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CareDx's Beneish M-Score falls into.


STU:1K9
74GF Score
CareDx Inc STU:1K9
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CareDx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CareDx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5284+0.528 * 0.9817+0.404 * 1.2954+0.892 * 1.1038+0.115 * 0.9013
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9319+4.679 * -0.19284-0.327 * 1.0564
=-3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €38.6 Mil.
Revenue was 101.81 + 92.562 + 85.247 + 75.151 = €354.8 Mil.
Gross Profit was 72.721 + 62.234 + 59.13 + 50.304 = €244.4 Mil.
Total Current Assets was €233.0 Mil.
Total Assets was €355.6 Mil.
Property, Plant and Equipment(Net PPE) was €47.0 Mil.
Depreciation, Depletion and Amortization(DDA) was €17.9 Mil.
Selling, General, & Admin. Expense(SGA) was €193.6 Mil.
Total Current Liabilities was €68.5 Mil.
Long-Term Debt & Capital Lease Obligation was €15.4 Mil.
Net Income was 2.43 + -3.508 + 1.427 + -7.428 = €-7.1 Mil.
Non Operating Income was -0.804 + 0.225 + -0.091 + -0.241 = €-0.9 Mil.
Cash Flow from Operations was 3.748 + 18.244 + 31.829 + 8.579 = €62.4 Mil.
Total Receivables was €66.1 Mil.
Revenue was 78.334 + 82.683 + 74.678 + 85.723 = €321.4 Mil.
Gross Profit was 52.05 + 55.761 + 49.835 + 59.711 = €217.4 Mil.
Total Current Assets was €324.0 Mil.
Total Assets was €452.9 Mil.
Property, Plant and Equipment(Net PPE) was €54.7 Mil.
Depreciation, Depletion and Amortization(DDA) was €18.1 Mil.
Selling, General, & Admin. Expense(SGA) was €188.3 Mil.
Total Current Liabilities was €78.9 Mil.
Long-Term Debt & Capital Lease Obligation was €22.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(38.566 / 354.77) / (66.124 / 321.418)
=0.108707 / 0.205726
=0.5284

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(217.357 / 321.418) / (244.389 / 354.77)
=0.676244 / 0.688866
=0.9817

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (233.027 + 47.023) / 355.569) / (1 - (323.971 + 54.685) / 452.915)
=0.212389 / 0.163958
=1.2954

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=354.77 / 321.418
=1.1038

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.056 / (18.056 + 54.685)) / (17.872 / (17.872 + 47.023))
=0.248223 / 0.275399
=0.9013

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(193.649 / 354.77) / (188.267 / 321.418)
=0.545844 / 0.585739
=0.9319

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((15.429 + 68.467) / 355.569) / ((22.267 + 78.888) / 452.915)
=0.235949 / 0.223342
=1.0564

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-7.079 - -0.911 - 62.4) / 355.569
=-0.19284

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CareDx has a M-score of -3.63 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.57 mean?
CareDx (STU:1K9) has a Beneish M-Score of -3.57 as of Jul. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CareDx and its competitors. According to the industry distribution chart, CareDx ranks #22 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 11.3%.
Is CareDx's Beneish M-Score too high?
CareDx's current Beneish M-Score is -3.57. Based on the distribution chart, CareDx ranks #22 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, CareDx has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Beneish M-Score compare to PSNL and OPK?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #22 out of 194 companies for Beneish M-Score. This places CareDx in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CareDx and its competitors. CareDx's current Beneish M-Score is -3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.45, compared to a current price of €25.60 — trading 38.8% above its estimated fair value. The current Beneish M-Score is -3.57. CareDx's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For CareDx (STU:1K9), the current Beneish M-Score is -3.57 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareDx (STU:1K9) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of €25.60 is trading 38.8% above its estimated GF Value™ of €18.45. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for STU:1K9:

  • Beneish M-Score: -3.57
  • GF Value™: €18.45 vs. price of €25.60 (38.8% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CareDx Business Description

Other Exchanges CDNA:USA
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
74GF Score

Get the complete analysis for STU:1K9

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.60
Price
€18.45
GF Value